Skip global navigation and read the article

Skip global navigation and go to local navigation

Skip global navigation and go to footer navigation



Home  > Press Release  > The key royal jelly component 10-hydroxy-2-decenoic acid protects against bone loss via FFAR4

The key royal jelly component 10-hydroxy-2-decenoic acid protects against bone loss via FFAR4

Abstract

The supplementation of royal jelly (RJ) is known to provide a variety of health benefits, including anti-inflammatory and anti-obesity effects. RJ treatment also reportedly protects against bone loss, but no single factor in RJ has yet been identified as an anti-osteoporosis agent. Here we fractionated RJ and identified 10-hydroxy-2-decenoic acid (10H2DA) as a key component involved in inhibiting osteoclastogenesis based on mass spectrometric analysis. We further demonstrated free fatty acid receptor 4 (FFAR4) as directly interacting with 10H2DA; binding of 10H2DA to FFAR4 on osteoclasts inhibited receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced activation of NF-κB signaling, thereby attenuating the induction of nuclear factor of activated T cells (NFAT) c1, a key transcription factor for osteoclastogenesis. Oral administration of 10H2DA attenuated bone resorption in ovariectomized mice. These results suggest a potential therapeutic approach of targeting osteoclast differentiation by the supplementation of RJ, and specifically 10H2DA, in cases of pathological bone loss such as occur in postmenopausal osteoporosis.

Journal Article

JOURNAL:
Journal of Biological Chemistry

TITLE:
The key royal jelly component 10-hydroxy-2-decenoic acid protects against bone loss via FFAR4

DOI:
https://doi.org/10.1074/jbc.RA120.013821

Correspondence to

Tomoki NAKASHIMA, Professor
Department of Cell Signaling,
Graduate School of Medical and Dental Sciences,
Tokyo Medical and Dental University(TMDU)
E-mail:naka.csi(at)tmd.ac.jp



*Please change (at) in e-mail addresses to @ on sending your e-mail to contact personnels.